Top Markets
#1 Derive Derive +33.22%
#2 Cross Cross +20.16%
#3 Geodnet Geodnet +12.50%
#4 Gama Token Gama Token +9.18%
#5 Biconomy Biconomy +9.08%
#6 Steakhouse ETH Morpho Vault Steakhouse ETH Morpho Vault +7.14%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +6.82%
#8 The Bitcoin Bull The Bitcoin Bull +6.60%
#9 Cap Cap +6.32%
#10 Based Based +6.22%
Coin of the day
Derive Derive
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
MetaVia Inc. MetaVia Inc.

MetaVia Inc.

MTVA
Classement en actions #35877
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Prix de l'action
$1.51
Dernière synchronisation: 2026-08-14
Capitalisation boursière
$3.32M
Changement (1 jour)
3.42%
Changement (1 an)
-78.55%
Pays
US
Échange MetaVia Inc. (MTVA)

Catégorie

Healthcare
Historique du prix de l'action pour MetaVia Inc. (MTVA)
Prix de clôture le plus élevé : $1.46 le 2026-08-01

Prix de clôture le plus bas : $27.36 le 2024-11-01
Historique du prix de l'action de MetaVia Inc. de 2024 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) -43.25%
2025 -62.61%
2024 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $505.24 28.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $846.09 29.41%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $731.69 6.47%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.07K -6.40%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $251.82 11.75%
BE